Latest Breaking News On - Bridgebio pharma inc - Page 14 : comparemela.com

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive upfront payment of USD 100 million with.

BridgeBio Pharma (BBIO) and Kyowa Kirin Partner $100M Upfront Payment for Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

BridgeBio Pharma and Kyowa Kirin Announce Partnership with

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive.

Blueshift Asset Management LLC Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Blueshift Asset Management LLC purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,482 shares of the company’s stock, valued at approximately $435,000. Several other large investors have also recently made changes to […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 06, 2024 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 05, 2024, the.